VWF and platelet-type von Willebrand disease: The authors provided further evidence of the utility of ristocetin-induced platelet agglutination/aggregation (RIPA) and RIPA mixing studies to help differentially identify type 2B von Willebrand disease (VWD) vs platelet type (PT) VWD.